UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2025


BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

Delaware
001-01136
22-0790350
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S Employer Identification No.)
Route 206 & Province Line Road, Princeton, New Jersey 08543
(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (609) 252-4621


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.000% Notes due 2025
BMY25
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Celgene Contingent Value Rights
CELG RT
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 7.01
Regulation FD Disclosure.
 
On January 13, 2025, Bristol-Myers Squibb Company (the “Company”) posted an investor presentation to its website at: www.bms.com/investors/events-and-presentations.html. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities thereof, nor shall it be incorporated by reference into any filing by the Company under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

Exhibit
No.
 
Description
   
 
Investor presentation of Bristol-Myers Squibb Company dated January 13, 2025.
104
 
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
 
       
Dated: January 13, 2025
By:
/s/ Amy Fallone
 
 
Name:
Amy Fallone
 
 
Title:
Corporate Secretary
 




Exhibit 99.1

 43rd Annual J.P. Morgan Healthcare Conference  January 13th, 2025  Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer 
 

 Forward Looking Statements and Non-GAAP Financial Information  2  This presentation (as well as the oral statements made with respect to the information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to: (i) New laws and regulations, (ii) Our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) Our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) Difficulties or delays in the development and commercialization of new products, (v) Difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) Adverse outcomes in legal or regulatory proceedings, (vii) Risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) Political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company’s most recent annual report on Form 10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and Exchange Commission’s website, on the Company’s website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed.  In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise.  This presentation includes certain non-Generally Accepted Accounting Principles (“GAAP”) financial measures that we use to describe the Company’s performance. The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company’s baseline performance, supplement or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods. This presentation also provides certain revenues and expenses or other financial measures excluding the impact of foreign exchange (“Ex-FX”). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.  The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as a substitute for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable financial measure are available on our website at www.bms.com/investors.  Also note that a reconciliation of forward-looking non-GAAP measures, including non-GAAP Earnings per share (EPS), to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. 
 

 The next chapter for BMS comes into focus  3  January 2024  Outlined journey to deliver sustained top-tier growth by end of the decade  Highlighted enablers:  Performance of key growth brands  Delivery of mid-late-stage pipeline assets  Focused on importance of execution  Today  Key first and/or best in class medicines driving Growth Portfolio*  Entering data-rich period, with multiple registrational readouts to define pipeline potential  Focusing on disciplined execution  *See Appendix Slide for composition of Growth Portfolio 
 

 Advanced growth portfolio with double-digit sales growth  Expanded presence in key TAs  Re-established presence in neuroscience with Cobenfy  Extended immuno-oncology portfolio durability with Opdivo Qvantig  Advanced late-stage assets with significant potential  Bolstered financial position  Successful integration of strategic acquisitions  Achieved majority of ~$1.5 billion productivity program and reinvested savings into high-ROI opportunities  Progress towards $10 billion debt pay down commitment1  2024 execution has strengthened our foundation  4  →  Stronger portfolio, pipeline & financial flexibility entering 2025  1. Relative to the total debt level as of March 31, 2024 
 

 Delivering breakthrough medicines to even more patients even faster and compelling returns to our shareholders  Overarching strategic focus: Achieve sustained top-tier growth by end of the decade  5  Focusing on transformational medicines in areas where we have a competitive advantage  Driving operational excellence throughout the organization  Strategically allocating capital for long-term growth and returns  → 
 

 Focusing on transformational medicines where we have competitive advantages  6  Key marketed products  Key Ph 2/3 programs  Investment priorities  Oncology/Hematology  Protein degradation  Cell therapy  Complex biologics  Radiopharmaceuticals  Cardiovascular  Thrombosis  Cardiomyopathies  Heart failure  Neuroscience   Neuropsychiatry  Neurodegeneration   Immunology  Controlling inflammation  Resetting immune memory  Promoting homeostasis   21  5  6  8  40 Total 
 

 Five products key to Growth Portfolio performance  7  Growth Portfolio expected to exceed 50% of revenues in 2025  *See “Forward-Looking Statements and Non-GAAP Financial Information.”; MDS: myelodysplastic syndrome; MF: myelofibrosis; oHCM: obstructive hypertrophic cardiomyopathy; nHCM: non-obstructive hypertrophic cardiomyopathy; SoC: standard of care; NSCLC: non-small cell lung cancer  First–in-class treatment in 1L MDS anemia with broad label  Potential MF anemia expansion with Phase 3 data expected in 2025*  First-in-class treatment in oHCM  nHCM expansion opportunity with Phase 3 data expected in 2025*  Best-in-class CD19 CAR-T across the broadest array of B-cell malignancies   Expanded manufacturing capabilities to unlock full potential   Novel first-in-class schizophrenia treatment with multiple high potential expansion opportunities  Launched late October 2024  First–in-class treatment, now a SoC in 1L melanoma  Exploring indication expansions (e.g., 1L NSCLC) 
 

 Cobenfy launch off to a strong start with the first indication for schizophrenia…  8  IQVIA Weekly NPA (Rapid) & APLD; Cobenfy’s TRx is overall indications without normalization; TRx are projected at national level   Cobenfy TRx  “I had lots of hope for this medication, but no expectations. But now, I can’t wait to try it on more patients.   These results are phenomenal. This medicine makes you a hero and doctors want to be heroes…” — Dr. Parks in Cary, IL  Thanksgiving  Christmas   & New Years  01  Consistent customer feedback highlights benefits of unique MoA across the three domains of schizophrenia  02  Cobenfy TRx performance is aligned to our expectations and ahead of branded schizophrenia launch benchmarks  03  Medicare & Medicaid coverage currently tracking ahead of expectations  04  Broader Commercial coverage expected in 2H25 
 

 …with several potential indications with multi-billion-dollar peak sales over the decade  9  Expected clinical data readout every year through the end of the decade  Ongoing registrational study readout  Planned registrational study readout  Alzheimer’s Disease Cognition  >6M1 people living with AD in U.S.   2025  2026  2027  2028  2029  2030+  Alzheimer’s Disease Agitation >6M1 people living with AD in U.S.   Bipolar I Disorder Impacts ~1.4M3 patients in U.S.  Alzheimer’s Disease Psychosis(ADEPT-1 & 4)  >6M1,2 people living with AD in U.S.   Adjunctive Schizophrenia (ARISE)  Expansion within schizophrenia  Alzheimer’s Disease Psychosis (ADEPT-2)  >6M1,2 people living with AD in U.S.   Autism Spectrum Disorder (Irritability)  ~1.6M3 patients in U.S.  Long-Acting Injectable   *See “Forward-Looking Statements and Non-GAAP Financial Information.”1. “Alzheimer’s Disease Association Facts and Figures,” 2023. 2. Represents 40% of Alzheimer’s disease 3. DRG – Clarivate, as of July 2023 
 

 2025  2025  Entering data rich period with multiple catalysts  10  2025–2027 key milestones*  Reblozyl TD MF Associated Anemia (INDEPENDENCE)  Opdualag Adjuvant Melanoma (RELATIVITY-098)  CAMZYOS nHCM (ODYSSEY)  Cobenfy Adjunctive Schizophrenia (ARISE)  Cobenfy Alzheimer’s Disease Psychosis (ADEPT-2)  CD19 NEX-T Autoimmune Diseases (Breakfree-1 & 2)  Krazati 1L NSCLC (TPS <50%) (KRYSTAL-17)  EGFR x HER3 ADC Advanced Solid Tumors1  RYZ101 1L ES-SCLC  LCM pivotal data  2026  Milvexian ACS & SSP (LIBREXIA)  Admilparant IPF (ALOFT-IPF)  Iberdomide RRMM (EXCALIBER-RRMM)  Mezigdomide RRMM (SUCCESSOR-1 & 2)  Arlo-cel RRMM (QUINTESSENTIAL)  RYZ101 2L+ GEP-NETs (ACTION-1)  NME registrational data  Key next wave early-stage data  2026  Sotyktu SLE (POETYK SLE-1 & 2)  Cobenfy Alzheimer’s Disease Psychosis (ADEPT-4 & 1)  2026  Golcadomide 1L FL (GOLSEEK-2)  MYK-224 HFpEF (AURORA)  2027  AR LDD mCRPC (rechARge)  2027  Anti-MTBR-tau Alzheimer’s Disease (TargetTau-1)  2027  Milvexian AF (LIBREXIA)  REBLOZYL 1L NTD MDS Associated Anemia (ELEMENT)  Sotyktu Sjogren’s Syndrome (POETYK SjS-1)  *See “Forward-Looking Statements and Non-GAAP Financial Information” NME: New Molecular Entity, LCM: Life Cycle Management 1: Trial conducted by SystImmune  
 

 CELMoDs: Potential to raise efficacy bar with highly potent protein degraders across hematologic malignacies  11  Potential new oral options with compelling anti-tumor effects and immune stimulation  CELMoDs offer a tailored approach of combinable regimens across patient segments2  Multiple Myeloma  Iberdomide & Mezigdomide   Potential new foundations in the multiple myeloma treatment landscape with four ongoing pivotal trials  Iberdomide has the potential to be a new SoC in NDMM as post-transplant maintenance  CELMoDs offer potential combinable novel regimens in RRMM including iberdomide with anti-CD38 antibodies & mezigdomide with proteosome inhibitors   >30K transplant eligible NDMM patients in U.S./EU1  Phase 3 data expected: 2029  >70K RRMM patients in U.S./EU1  Phase 3 data expected: 2026*  Lymphoma  Golcadomide  Evaluating novel golcadomide combination regimens across aggressive & indolent lymphomas  Ongoing pivotal trial evaluating golcadomide + R-CHOP in 1L high-risk LBCL  >60K 1L LBCL patients in U.S./EU1  Phase 3 data expected: 2028*  *See “Forward-Looking Statements and Non-GAAP Financial Information” 1. Decision Resource Group, BMS Internal Analysis – Treated Population; 2. Please refer to ct.gov details: NCT04975997; NCT05827016; NCT05519085; NCT05552976; NCT06356129   →  → 
 

 Milvexian: Potential to redefine anticoagulant therapy for thrombotic diseases  12  *See “Forward-Looking Statements and Non-GAAP Financial Information” 1. Developed in partnership with Johnson & Johnson 2. Please refer to ct.gov details: NCT05702034; NCT05754957; NCT05757869 3. Decision Resource Group, BMS Internal Analysis; EU represents EU5 – Incidence 4. Decision Resource Group, BMS Internal Analysis – Diagnosed Prevalence  Focused on addressing unmet medical need across three large indications1,2  LIBREXIA-STROKE  Secondary Stroke Prevention (25mg BID)  Combining with dual antiplatelet therapy  FXa’s not used due to excess bleeding risk  Potential for improved efficacy (e.g., stroke) without increasing bleeding risk  ~1.3 million patients in U.S./EU3  Phase 3 data expected: 2026*  LIBREXIA-ACS  Acute Coronary Syndrome (25mg BID)  Similar underlying pathophysiology and treatment as stroke  FXa’s not used due to excess bleeding risk  Potential for improved efficacy (e.g., CV death, MI) without increasing bleeding risk  ~2 million patients in U.S./EU3  Phase 3 data expected: 2026*  LIBREXIA-AF  Atrial Fibrillation (100mg BID)   Monotherapy agent vs. apixaban; only oral FXIa potential in AF  Potential for comparable efficacy with lower bleeding risk  ~40% of patients untreated or undertreated due to bleeding risk  ~14 million patients in U.S./EU4  Phase 3 data expected: 2027*  FXla inhibition offers promising next-generation anticoagulant paradigm to improve patient care  →  →  → 
 

 Admilparant (LPA1 antagonist): Potential to transform the treatment of pulmonary fibrosis  13  ALOFT-IPF & ALOFT–PPF2: Phase 3 registrational studies following a robust Phase 2 program  Significant unmet need  IPF & PPF are fatal lung diseases with 3–5 years median survival1  Patients continue to experience progressive decline in lung function on approved therapies with limited treatment adherence due to tolerability  U.S./EU prevalence3: IPF: 233K, PPF: 485K  Pulmonary Fibrosis market: >$4 billion in sales in 20234  Clinical rationale  Deliver a new product with potentially improved efficacy and tolerability profile over current treatment options   >60% improvement in lung-function decline vs. placebo with 60 mg dose in phase 2 in IPF; ~70% improvement in PPF5,6  Phase 3 ALOFT-IPF & ALOFT-PPF ongoing  Phase 3 data expected: 2026*/2028*  *See “Forward-Looking Statements and Non-GAAP Financial Information” 1. Raghu. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824; 2. Please refer to ct.gov details: NCT06003426; NCT06025578; 3. Decision Resource Group; 4. Evaluate Pharma (Respiratory Disorders, Pulmonary Fibrosis); 5. Corte TJ, et al. Am J Respir Crit Care Med. 2023;207:A2785; 6. Corte TJ, et al. ERS 2023 [Presentation #RCT800]; IPF = Idiopathic pulmonary fibrosis; PPF = Progressive Pulmonary Fibrosis  Potential to be first and best-in-class, redefining the standard of care in pulmonary fibrosis  →  → 
 

 Upcoming launch catalysts build upon existing portfolio andwill further strengthen our growth profile  14  2028–2030  2026  Breyanzi   MZL 3L+  Camzyos  nHCM  Cobenfy   Adjunctive Schizophrenia   Opdivo  HCC Adjuvant  Opdivo+chemo   Peri-adjuvant MIUC  Reblozyl  MF anemia 1L+  Sotyktu  PsA  2027  Cobenfy   Alzheimer’s Disease Psychosis  Krazati   CRC 2L  Opdualag   Adjuvant Stage 3–4 Melanoma  Reblozyl   Alpha Thalassemia2  iberdomide   RRMM  mezigdomide   RRMM  obexelimab   IgG4-Related Diseases2  RYZ101   GEP-NETs (SSTR+)  Cobenfy   Alzheimer’s Disease Agitation  Cobenfy   Alzheimer’s Disease Cognition  Cobenfy   Autism Irritability  Cobenfy   Bipolar I Disorder  admilparant   PPF  arlo-cel  MM 2L+  CD19 NEX-T   Auto-Immune Indications  admilparant   IPF  anti-CCR8  Solid Tumors  AR LDD  Prostate Cancer  arlo-cel   MM 4L+  Sotyktu   SLE  Reblozyl   MDS 1L NTD anemia  Sotyktu   Sjogren’s Syndrome  milvexian   Atrial Fibrillation  milvexian   SSP  RYZ101   Breast Cancer 3L+ E+H2- SSTR+  RYZ101   SCLC 1L ES (SSTR+)  golcadomide   LBCL (high-risk) 1L  HELIOS CELMoD  Solid Tumors  milvexian   ACS  MYK-224   HFpEF  Krazati   NSCLC 1L KRAS (TPS <50%)  Nivo+Rela HD+Chemo   NSCLC 1L  Krazati  NSCLC 1L KRAS (TPS ≥50%)  EGFR x HER3 ADC   Additional Solid Tumors  golcadomide   FL 3L+  iberdomide   NDMM post-HSCT maintenance  atigotatug   SCLC 1L ES  BCMA x GPRC5D dual CAR-T RRMM  CD19 NEX-T   SLE Severe Refractory  EGFR x HER3 ADC   Solid Tumors  PRMT5i  Solid Tumors  2025  Opdivo + Yervoy  CRC 1L+ MSI High  Opdivo + Yervoy  HCC 1L  *See “Forward-Looking Statements and Non-GAAP Financial Information”; Not an exhaustive list of assets, programs, or indications; subject to positive registrational trials and regulatory approval; planned launches as of December 31st, 2024; 1. Opdivo Qvantig January 2025 SC formulation launch, extending immuno-oncology franchise into early 2030s; 2. Ex-US study  Currently marketed   Growth Portfolio  Growth Portfolio LCM  NME  NME LCM  →  1 
 

 Continuing to drive operational excellence  15  Note: See “Forward-Looking Statements and Non-GAAP Financial Information”  Leveraging technology and AI across the organization to   accelerate pace of innovation, drive operational excellence and reduce cost base  Annualized ~$1.5B in cost savings to be realized by the end of 2025  Reinvesting savings in high return growth initiatives  Continuing to review cost structure   Evolving our organization  Prioritizing the highest value programs  Raising the probability of success from first-in-human to approval  Reducing cycle times to bring medicines to patients faster  Improving R&D productivity  Increasing efficiency  Maintaining a highly patient-centric approach  Greater focus on accountability and acting with sense of urgency  Streamlining the organization and simplifying ways of working 
 

 Investments in innovation  Investing in our Growth Portfolio and R&D   Pursuing business development and partnerships  R&D investment of ~$28B over the past 3 years1,2,3  Business development investment of ~$27B over the past 3 years1,4  Balance sheet strength  Maintaining a strong balance sheet that provides strategic flexibility   Planned debt repayment of $10B by 1H’265  Strong long-term investment grade credit ratings  Returning capital to shareholders  Solid track record of returning capital to shareholders through ~$14B in dividends and ~$16B in share repurchases over the past 3 years1  93 consecutive years of dividend payments6  Strategically allocating capital for long-term growth  16  1. For the three years ended 9/30/2024 2. See “Forward-Looking Statements and Non-GAAP Financial Information” 3. Refer to GAAP to Non-GAAP Reconciliation in Appendix 4. Represents Acquisition and other payments, net of cash acquired 5. Relative to the total debt level as of March 31, 2024 6. Latest dividend increase declared 12/11/2024 and payable 2/3/2025 on common stock of the company 
 

 Reshaping BMS to deliver sustained top-tier growth & long term shareholder returns   17  Focusing on transformational medicines where we have an advantage   Driving operational effectiveness throughout the organization  Strategically allocating capital   Significantly younger, more diversified and de-risked portfolio which is more balanced across leading TAs  Potential 10+ NMEs & 30+ major LCM indications in 2025–2030*  Increased strategic flexibility resulting from financial discipline  Increasing conviction in ability to deliver top-tier growth  →  *See “Forward-Looking Statements and Non-GAAP Financial Information”  
 

 

 (Unaudited, dollars in millions)  Three Months Ended  December 31, 2021  Year Ended   December 31, 2022  Year Ended  December 31, 2023  Nine Months Ended  September 30, 2024  Three Years Ended  September 30, 2024  Research and development  $ 2,518  $9,509  $9,299  $7,968  $29,294  Specified items(a)  -  308  187  974  1,469  Research and Development excluding specified items  $2,518  $9,201  $9,112  $6,994  $27,825  Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items   For the Three Year Period Ended September 30, 2024  (a) An explanation of these non-GAAP financial measures are available on our website at bms.com/investors  19 
 

 10  Growth Portfolio  Legacy Portfolio  1. Other Growth Brands: Onureg, Inrebic, Nulojix, Empliciti, & Royalty revenues  Other Growth Brands1  Other Mature Brands 
 

 2024 environmental, social, and governance progress   21  Named to the 2023 Dow Jones Sustainability™ World Indices1  ASPIRE 10-year strategy announced, expanding access to patients in LMICs   6 consecutive years of beingawarded a top score on Disability Equality Index®  SBTi validation of our near-term and long-term net-zero targets  ATOM coalition collaboration announced to provide access to our immuno-oncology therapies like OPDIVO® in select LMICs  ESG strategy  Advancing patienthealth around the world  Fostering a high-performing & inclusive global workforce  Reducing our environment impact   One of America’s 100 Most JUST Companies, jumping from 349th position to 100th  2024 Climate Change Report – Published  Access to Medicine Index (ATMI) BMS climbed two spots to 13th out of 20 since 2022  10 consecutive years of being included in the FTSE4Good Index Series  1. Index recognizes progress increasing workforce representation, reducing environmental impact, enhancing data privacy and cyber security programs, establishing principles for responsible artificial intelligence 
 

 Clinical Development Portfolio — Phase I and II   22  Krazati  1L Non-Small Cell Lung Cancer PD-L1<50%  Breyanzi  RR Marginal Zone Lymphoma  Golcadomide  RR Follicular Lymphoma  Arlocabtagene autoleucel (GPRC5D CAR T)  ª RR Multiple Myeloma   Reblozyl  A-Thalassemia  MYK-224  ª Heart Failure with preserved Ejection Fraction  Obstructive Hypertrophic Cardiomyopathy  afimetoran  ª Systemic Lupus Erythematosus  BMS-986322 (TYK2 Inhibitor)  ª Moderate-to-Severe Psoriasis  Sotyktu  Discoid Lupus Erythematosus  Anti-MTBR Tau  ª Alzheimer’s Disease  Anti-CCR8  ª Solid Tumors  BMS-986460  ª Prostate Cancer  BMS-986463  ª Solid Tumors  BMS-986484  ª Solid Tumors  BMS-986490  ª Solid Tumors  FAK CELMoD  ª Solid Tumors  IKZF-PD CELMoD  ª Solid Tumors  izalontamab brengitecan (EGFRxHER3 ADC)  ª 1L Non-Small Cell Lung Cancer*  Solid Tumors*  Metastatic Non-Small Cell Lung Cancer  Helios CELMoD  ª Solid Tumors  JNK Inhibitor  ª Solid Tumors  KRASG12D Inhibitor  ª Solid Tumors  PRMT5 Inhibitor  ª Solid Tumors  RYZ101  Extensive Stage Small Cell Lung Cancer  HR+/HER2- Unresectable Metastatic Breast Cancer  RYZ801  ª Hepatocellular Carcinoma  SOS1 Inhibitor  ª Solid Tumors  BCL6 LDD  Lymphoma  CD33-GSPT1 ADC  ª Acute Myeloid Leukemia  CD33 NKE  ª Acute Myeloid Leukemia  CK1α Degrader  ª Hematologic Malignancies  Dual Targeting BCMAxGPRC5D CAR T  ª RR Multiple Myeloma  HbF Activating CELMoD  ª Sickle Cell Disease  BMS-986454  ª Autoimmune Disease  CD19 NEX-T  Autoimmune Diseases  ª Severe Refractory Systemic Lupus Erythematosus  IL2-CD25  ª Autoimmune Disease  PKCθ Inhibitor  ª Autoimmune Disease  BMS-986495  ª Neurodegenerative Diseases  CD19 NEX-T  Multiple Sclerosis  eIF2B Activator  ª Alzheimer’s Disease  FAAH/MGLL Dual Inhibitor  ª Neurodegenerative Diseases  TRPC4/5 Inhibitor  ª Mood and Anxiety Disorders  BMS-986465 (TYK2 Inhibitor)  ª Neuroinflammation Disorders  Data as of Jan 13th, 2025  Phase I  Phase II  Hematology  Neuroscience  Oncology  Immunology  CV  * Partner-run study   NME leading indication 
 

 Clinical Development Portfolio — Phase III   23  AR LDD  ª Metastatic Castration-Resistant Prostate Cancer   Atigotatug (Anti-Fucosyl GM1) + nivolumab  ª 1L Extensive Stage Small Cell Lung Cancer  Krazati  1L Non-Small Cell Lung Cancer PD-L1≥50%  2L Colorectal Cancer  Nivolumab + Relatlimab HD  ª 1L Non-Small Cell Lung Cancer  OPDIVO  Adjuvant Hepatocellular Carcinoma  Peri-adjuvant Muscle-Invasive Urothelial Carcinoma  Stage IB-IIIA Adjuvant Non-Small Cell Lung Cancer*  OPDUALAG  Adjuvant Melanoma  RYZ101  ª 2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors  SC nivolumab + relatlimab + rHuPH20  ª 1L Melanoma  Golcadomide  ª High Risk 1L Large B-cell Lymphoma  (Arlocabtagene autoleucel) (GPRC5D CAR T)  2–4L Multiple Myeloma  Iberdomide  ª 2L+ Multiple Myeloma   Post-ASCT Maintenance Newly Diagnosed Multiple Myeloma  Mezigdomide  2L+ Multiple Myeloma Kd  ª 2L+ Multiple Myeloma Vd  Reblozyl  1L TD Myelofibrosis Associated Anemia    1L NTD Myelodysplastic Syndrome Associated Anemia  CAMZYOS  Non-Obstructive Hypertrophic Cardiomyopathy  Milvexian  Acute Coronary Syndrome*  Atrial Fibrillation*  Secondary Stroke Prevention*  Cendakimab  ª Eosinophilic Esophagitis  Eosinophilic Gastroenteritis #  Admilparant  ª Idiopathic Pulmonary Fibrosis  LPA1 Antagonist  Progressive Pulmonary Fibrosis  Obexelimab  ª IgG4-Related Disease  Sotyktu  Psoriatic Arthritis  Sjögren's Syndrome  Systemic Lupus Erythematosus  Cobenfy  Adjunctive Schizophrenia  Psychosis in Alzheimer’s Disease  AUGTYRO  ROS1 NSCLC (EU)  NTRK Pan-Tumor (EU, JP)  OPDIVO  Peri-adjuvant Non-Small Cell Lung Cancer (EU)  OPDIVO+YERVOY  1L Hepatocellular Carcinoma (US, EU, JP)  1L+ Microsatellite Instability High Colorectal Cancer (JP)  OPDIVO QVANTIG  ª 2L Renal Cell Carcinoma (EU)  Breyanzi  RR Follicular Lymphoma (EU)  Development Partnerships:   AUGTYRO: Zai Lab; izalontamab brengitecan (EGFRxHER3 ADC): SystImmune; Cobenfy: Zai Lab; Krazati: Zai Lab; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; OPDIVO, YERVOY, OPDUALAG: Ono; PKCθ Inhibitor: Exscientia; Reblozyl: Merck; rHuPH20: Halozyme  Data as of Jan 13th, 2025  Phase III  Registration US, EU, JP  Hematology  Neuroscience  Oncology  Immunology  CV  * Partner-run study   NME leading indication  # Japan only 
 


v3.24.4
Document and Entity Information
Jan. 13, 2025
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 13, 2025
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Central Index Key 0000014272
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One Route 206 & Province Line Road
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08543
City Area Code 609
Local Phone Number 252-4621
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE

Bristol Myers Squibb (PK) (USOTC:BMYMP)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Bristol Myers Squibb (PK) 차트를 더 보려면 여기를 클릭.
Bristol Myers Squibb (PK) (USOTC:BMYMP)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Bristol Myers Squibb (PK) 차트를 더 보려면 여기를 클릭.